Serum C-reactive Protein (CRP) Levels in Cancer Patients Are Linked with Tumor Burden and Are Reduced by Anti-hypertensive Medication

Overview

Journal Inflammation

Specialties Allergy & Immunology
Pathology

Date 2009 Apr 18

PMID 19373547

Citations 19

Authors

Michael I Koukourakis

Georgia Kambouromiti

Dimitra Pitsiava

Pelagia Tsousou

Maria Tsiarkatsi

George Kartalis

Affiliations

Soon will be listed here.

Abstract

High levels of CRP relate with advanced disease and poor prognosis of cancer patients. CRP serum levels were measured in 684 cancer patients who had undergone complete surgery or inoperable patients. Patients with inoperable tumors had significantly higher CRP levels (1.21 +/- 2.2 vs. 0.40 +/- 0.4 mg/dL; p < 0.0001). No association with gender, diabetes, autoimmune disease, thyroid disease or allergy was noted. Significantly higher CRP levels were noted in operated patients with hypertension (0.55 +/- 0.5 vs. 0.35 +/- 0.4; p = 0.001), coronary disease (0.73 +/- 0.8 vs. 0.39 +/- 0.4; p = 0.01) and obesity (0.51 +/- 0.5 vs. 0.37 +/- 0.4; p = 0.04). On the contrary, analysis in the group of inoperable patients showed that hypertensive patients had significantly lower CRP levels (0.64 +/- 1.0 vs. 1.36 +/- 2.4; p = 0.008). Although the tumor itself is the main factor defining increased CRP levels in cancer patients, hypertension, coronary disease and obesity are also linked with high CRP levels. Anti-hypertensive drugs appear as potent suppressors of the tumor-induced CRP production.

Citing Articles

Early on-treatment C-reactive protein and its kinetics predict survival and response in recurrent and/or metastatic head and neck cancer patients receiving first-line pembrolizumab.

Haas M, Lein A, Fuereder T, Schnoell J, Brkic F, Liu D Invest New Drugs. 2023; 41(5):727-736.

PMID: 37603206 PMC: 10560194. DOI: 10.1007/s10637-023-01388-x.

C-reactive protein, immunothrombosis and venous thromboembolism.

Dix C, Zeller J, Stevens H, Eisenhardt S, Cheung Tung Shing K, Nero T Front Immunol. 2022; 13:1002652.

PMID: 36177015 PMC: 9513482. DOI: 10.3389/fimmu.2022.1002652.

Lymphoma Severity and Type Are Associated With Aortic FDG Uptake by F-FDG PET/CT Imaging.

Vlachopoulos C, Koutagiar I, Georgakopoulos A, Pouli A, Sioni A, Giannouli S JACC CardioOncol. 2021; 2(5):758-770.

PMID: 34396292 PMC: 8352324. DOI: 10.1016/j.jaccao.2020.11.001.

Association between serum level soluble programmed cell death ligand 1 and prognosis in patients with non-small cell lung cancer treated with anti-PD-1 antibody.

Murakami S, Shibaki R, Matsumoto Y, Yoshida T, Goto Y, Kanda S Thorac Cancer. 2020; 11(12):3585-3595.

PMID: 33108686 PMC: 7705908. DOI: 10.1111/1759-7714.13721.

The Glasgow Prognostic Score is a significant predictor of peripheral T-cell lymphoma (PTCL) treated with CHOP-based chemotherapy and comparable with PTCL prognostic scores.

Huh S, Oh S, Lee S, Lee J, Kim S, Lee G Int J Hematol. 2019; 110(4):438-446.

PMID: 31250282 DOI: 10.1007/s12185-019-02693-z.

References

Lee J, Cho B, Bae M, Lee C, Park I, Kim D . Preoperative C-reactive protein levels are associated with tumor size and lymphovascular invasion in resected non-small cell lung cancer. Lung Cancer. 2008; 63(1):106-10. DOI: 10.1016/j.lungcan.2008.04.011. View

Ganapathi M, Rzewnicki D, Samols D, Jiang S, Kushner I . Effect of combinations of cytokines and hormones on synthesis of serum amyloid A and C-reactive protein in Hep 3B cells. J Immunol. 1991; 147(4):1261-5. View

Sawaki A, Kanemitsu Y, Mizuno N, Takahashi K, Nakamura T, Ioka T . Practical prognostic index for patients with metastatic pancreatic cancer treated with gemcitabine. J Gastroenterol Hepatol. 2008; 23(8 Pt 1):1292-7. DOI: 10.1111/j.1440-1746.2006.04734.x. View

Gortney J, Sanders R . Impact of C-reactive protein on treatment of patients with cardiovascular disease. Am J Health Syst Pharm. 2007; 64(19):2009-16. DOI: 10.2146/ajhp060542. View

Sainz J, Perez E, Gomez-Lopera S, Jurado M . IL1 gene cluster polymorphisms and its haplotypes may predict the risk to develop invasive pulmonary aspergillosis and modulate C-reactive protein level. J Clin Immunol. 2008; 28(5):473-85. DOI: 10.1007/s10875-008-9197-0. View

Rajagopalan S, Zannad F, Radauceanu A, Glazer R, Jia Y, Prescott M . Effects of valsartan alone versus valsartan/simvastatin combination on ambulatory blood pressure, C-reactive protein, lipoproteins, and monocyte chemoattractant protein-1 in patients with hyperlipidemia and hypertension. Am J Cardiol. 2007; 100(2):222-6. DOI: 10.1016/j.amjcard.2007.02.085. View

Macri A, Versaci A, Loddo S, Scuderi G, Travagliante M, Trimarchi G . Serum levels of interleukin 1beta, interleukin 8 and tumour necrosis factor alpha as markers of gastric cancer. Biomarkers. 2006; 11(2):184-93. DOI: 10.1080/13547500600565677. View

Gage J, Fonarow G, Hamilton M, Widawski M, Martinez-Maza O, Vredevoe D . Beta blocker and angiotensin-converting enzyme inhibitor therapy is associated with decreased Th1/Th2 cytokine ratios and inflammatory cytokine production in patients with chronic heart failure. Neuroimmunomodulation. 2004; 11(3):173-80. DOI: 10.1159/000076766. View

Yoshida S, Saito K, Koga F, Yokoyama M, Kageyama Y, Masuda H . C-reactive protein level predicts prognosis in patients with muscle-invasive bladder cancer treated with chemoradiotherapy. BJU Int. 2008; 101(8):978-81. DOI: 10.1111/j.1464-410X.2007.07408.x. View

10.

Robey F, Jones K, Tanaka T, Liu T . Binding of C-reactive protein to chromatin and nucleosome core particles. A possible physiological role of C-reactive protein. J Biol Chem. 1984; 259(11):7311-6. View

11.

Yang J, Wang J, Zhu S, Chen X, Wu H, Yang D . C-reactive protein augments hypoxia-induced apoptosis through mitochondrion-dependent pathway in cardiac myocytes. Mol Cell Biochem. 2008; 310(1-2):215-26. DOI: 10.1007/s11010-007-9683-3. View

12.

Casas J, Shah T, Hingorani A, Danesh J, Pepys M . C-reactive protein and coronary heart disease: a critical review. J Intern Med. 2008; 264(4):295-314. DOI: 10.1111/j.1365-2796.2008.02015.x. View

13.

Beer T, Lalani A, Lee S, Mori M, Eilers K, Curd J . C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trial. Cancer. 2008; 112(11):2377-83. DOI: 10.1002/cncr.23461. View

14.

Groblewska M, Mroczko B, Wereszczynska-Siemiatkowska U, Kedra B, Lukaszewicz M, Baniukiewicz A . Serum interleukin 6 (IL-6) and C-reactive protein (CRP) levels in colorectal adenoma and cancer patients. Clin Chem Lab Med. 2008; 46(10):1423-8. DOI: 10.1515/CCLM.2008.278. View

15.

Chung H, Kim J, Lee J, Song S, Chung J, Kwon O . Comparison of the validity of three biomarkers for gastric cancer screening: carcinoembryonic antigen, pepsinogens, and high sensitive C-reactive protein. J Clin Gastroenterol. 2008; 43(1):19-26. DOI: 10.1097/MCG.0b013e318135427c. View

16.

Schmeisser A, Soehnlein O, Illmer T, Lorenz H, Eskafi S, Roerick O . ACE inhibition lowers angiotensin II-induced chemokine expression by reduction of NF-kappaB activity and AT1 receptor expression. Biochem Biophys Res Commun. 2004; 325(2):532-40. DOI: 10.1016/j.bbrc.2004.10.059. View

17.

Marnell L, Mold C, Volzer M, Burlingame R, Du Clos T . C-reactive protein binds to Fc gamma RI in transfected COS cells. J Immunol. 1995; 155(4):2185-93. View

18.

Shiu Y, Lin J, Huang C, Jiang J, Wang L, Huang H . Is C-reactive protein a prognostic factor of colorectal cancer?. Dis Colon Rectum. 2008; 51(4):443-9. DOI: 10.1007/s10350-007-9133-z. View

19.

Gershov D, Kim S, Brot N, Elkon K . C-Reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an antiinflammatory innate immune response: implications for systemic autoimmunity. J Exp Med. 2000; 192(9):1353-64. PMC: 2193350. DOI: 10.1084/jem.192.9.1353. View

20.

Mold C, Gewurz H, Du Clos T . Regulation of complement activation by C-reactive protein. Immunopharmacology. 1999; 42(1-3):23-30. DOI: 10.1016/s0162-3109(99)00007-7. View